nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Etoposide—urinary bladder cancer	0.245	1	CbGbCtD
Raltegravir—UGT1A1—urine—urinary bladder cancer	0.0367	0.201	CbGeAlD
Raltegravir—CCR1—prostate gland—urinary bladder cancer	0.0321	0.175	CbGeAlD
Raltegravir—CCR1—seminal vesicle—urinary bladder cancer	0.0271	0.148	CbGeAlD
Raltegravir—CCR1—urethra—urinary bladder cancer	0.0215	0.117	CbGeAlD
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0184	0.155	CbGpPWpGaD
Raltegravir—CCR1—female reproductive system—urinary bladder cancer	0.0175	0.0956	CbGeAlD
Raltegravir—CCR1—vagina—urinary bladder cancer	0.0158	0.0865	CbGeAlD
Raltegravir—UGT1A1—prostate gland—urinary bladder cancer	0.0132	0.072	CbGeAlD
Raltegravir—CCR1—lymph node—urinary bladder cancer	0.0102	0.0559	CbGeAlD
Raltegravir—UGT1A1—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00963	0.0809	CbGpPWpGaD
Raltegravir—UGT1A1—renal system—urinary bladder cancer	0.00899	0.0491	CbGeAlD
Raltegravir—UGT1A1—Glucuronidation—UGT2B7—urinary bladder cancer	0.00885	0.0743	CbGpPWpGaD
Raltegravir—UGT1A1—Glucuronidation—UGT2B7—urinary bladder cancer	0.00717	0.0602	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—NQO1—urinary bladder cancer	0.00372	0.0312	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00312	0.0262	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—urinary bladder cancer	0.00301	0.0253	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTO2—urinary bladder cancer	0.00296	0.0248	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—NAT1—urinary bladder cancer	0.00296	0.0248	CbGpPWpGaD
Raltegravir—UGT1A1—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00285	0.0239	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—UGT2B7—urinary bladder cancer	0.0027	0.0227	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00267	0.0224	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00182	0.0153	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—UGT2B7—urinary bladder cancer	0.0018	0.0152	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0018	0.0151	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00175	0.0147	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00173	0.0145	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NAT1—urinary bladder cancer	0.00173	0.0145	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00171	0.0143	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—NAT2—urinary bladder cancer	0.00162	0.0136	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00158	0.0133	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00156	0.0131	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00142	0.012	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00141	0.0118	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—HPGDS—urinary bladder cancer	0.0013	0.0109	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTT1—urinary bladder cancer	0.00126	0.0106	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.00113	0.00952	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000957	0.00803	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—NAT2—urinary bladder cancer	0.000948	0.00796	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000935	0.00785	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—urinary bladder cancer	0.000871	0.00731	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000858	0.00721	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—urinary bladder cancer	0.0008	0.00672	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000761	0.00639	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000758	0.00636	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000735	0.00617	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GLI1—urinary bladder cancer	0.000719	0.00604	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000703	0.0059	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NQO1—urinary bladder cancer	0.000696	0.00585	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00063	0.0053	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000613	0.00515	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—urinary bladder cancer	0.000581	0.00488	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000579	0.00486	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000537	0.00451	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—urinary bladder cancer	0.000534	0.00448	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000512	0.0043	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000509	0.00428	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000502	0.00422	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000493	0.00414	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000468	0.00393	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TSC1—urinary bladder cancer	0.000463	0.00389	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000462	0.00388	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000441	0.0037	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000373	0.00313	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—S100B—urinary bladder cancer	0.000357	0.003	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000339	0.00284	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000327	0.00275	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000321	0.0027	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000313	0.00263	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000312	0.00262	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000297	0.0025	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTO2—urinary bladder cancer	0.000296	0.00248	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NAT1—urinary bladder cancer	0.000296	0.00248	CbGpPWpGaD
Raltegravir—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000293	0.000647	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—urinary bladder cancer	0.000291	0.000644	CcSEcCtD
Raltegravir—Asthenia—Gemcitabine—urinary bladder cancer	0.00029	0.000641	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—urinary bladder cancer	0.000289	0.00064	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000287	0.000636	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000287	0.000634	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—urinary bladder cancer	0.000287	0.000634	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—urinary bladder cancer	0.000286	0.000633	CcSEcCtD
Raltegravir—Pruritus—Gemcitabine—urinary bladder cancer	0.000286	0.000632	CcSEcCtD
Raltegravir—Nausea—Thiotepa—urinary bladder cancer	0.000285	0.000631	CcSEcCtD
Raltegravir—Urethral disorder—Methotrexate—urinary bladder cancer	0.000285	0.000631	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—urinary bladder cancer	0.000285	0.00063	CcSEcCtD
Raltegravir—Feeling abnormal—Etoposide—urinary bladder cancer	0.000284	0.000629	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000284	0.00239	CbGpPWpGaD
Raltegravir—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000284	0.000628	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TERT—urinary bladder cancer	0.000283	0.00238	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000282	0.000624	CcSEcCtD
Raltegravir—Pruritus—Fluorouracil—urinary bladder cancer	0.000281	0.000622	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000281	0.000621	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—urinary bladder cancer	0.000281	0.000621	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—urinary bladder cancer	0.00028	0.00062	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000278	0.000615	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000278	0.000614	CcSEcCtD
Raltegravir—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000277	0.000612	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—urinary bladder cancer	0.000276	0.00061	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000275	0.000608	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000275	0.000608	CcSEcCtD
Raltegravir—Urticaria—Etoposide—urinary bladder cancer	0.000274	0.000606	CcSEcCtD
Raltegravir—Body temperature increased—Etoposide—urinary bladder cancer	0.000273	0.000603	CcSEcCtD
Raltegravir—Abdominal pain—Etoposide—urinary bladder cancer	0.000273	0.000603	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—urinary bladder cancer	0.000272	0.000602	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—urinary bladder cancer	0.000272	0.000601	CcSEcCtD
Raltegravir—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000272	0.000601	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—urinary bladder cancer	0.000271	0.0006	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000271	0.000599	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000271	0.00227	CbGpPWpGaD
Raltegravir—Asthenia—Cisplatin—urinary bladder cancer	0.00027	0.000598	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00027	0.000597	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000269	0.000595	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000268	0.000593	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—urinary bladder cancer	0.000268	0.000592	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000268	0.000592	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—urinary bladder cancer	0.000267	0.00059	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000265	0.000587	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—urinary bladder cancer	0.000265	0.000585	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—urinary bladder cancer	0.000264	0.000584	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—urinary bladder cancer	0.000263	0.000581	CcSEcCtD
Raltegravir—Dizziness—Fluorouracil—urinary bladder cancer	0.000263	0.000581	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—urinary bladder cancer	0.000262	0.00058	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000262	0.00058	CcSEcCtD
Raltegravir—Chills—Methotrexate—urinary bladder cancer	0.000261	0.000577	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.00026	0.00218	CbGpPWpGaD
Raltegravir—Diarrhoea—Cisplatin—urinary bladder cancer	0.000258	0.00057	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000258	0.000569	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—urinary bladder cancer	0.000257	0.000569	CcSEcCtD
Raltegravir—Vomiting—Gemcitabine—urinary bladder cancer	0.000257	0.000568	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—urinary bladder cancer	0.000255	0.000564	CcSEcCtD
Raltegravir—Rash—Gemcitabine—urinary bladder cancer	0.000255	0.000564	CcSEcCtD
Raltegravir—Dermatitis—Gemcitabine—urinary bladder cancer	0.000255	0.000563	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—urinary bladder cancer	0.000255	0.000563	CcSEcCtD
Raltegravir—Hypersensitivity—Etoposide—urinary bladder cancer	0.000254	0.000562	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—urinary bladder cancer	0.000254	0.000561	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—urinary bladder cancer	0.000253	0.00056	CcSEcCtD
Raltegravir—Erythema—Methotrexate—urinary bladder cancer	0.000253	0.00056	CcSEcCtD
Raltegravir—Headache—Gemcitabine—urinary bladder cancer	0.000253	0.00056	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000253	0.000559	CcSEcCtD
Raltegravir—Vomiting—Fluorouracil—urinary bladder cancer	0.000253	0.000559	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000252	0.00212	CbGpPWpGaD
Raltegravir—Hepatitis—Doxorubicin—urinary bladder cancer	0.000252	0.000557	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000251	0.000554	CcSEcCtD
Raltegravir—Rash—Fluorouracil—urinary bladder cancer	0.000251	0.000554	CcSEcCtD
Raltegravir—Dermatitis—Fluorouracil—urinary bladder cancer	0.00025	0.000554	CcSEcCtD
Raltegravir—Headache—Fluorouracil—urinary bladder cancer	0.000249	0.000551	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000249	0.00055	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000248	0.000549	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—urinary bladder cancer	0.000248	0.000549	CcSEcCtD
Raltegravir—Asthenia—Etoposide—urinary bladder cancer	0.000248	0.000548	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000248	0.000548	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—urinary bladder cancer	0.000247	0.000546	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000247	0.000546	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—urinary bladder cancer	0.000246	0.000544	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000245	0.000543	CcSEcCtD
Raltegravir—Back pain—Methotrexate—urinary bladder cancer	0.000245	0.000542	CcSEcCtD
Raltegravir—Chills—Epirubicin—urinary bladder cancer	0.000244	0.00054	CcSEcCtD
Raltegravir—Pruritus—Etoposide—urinary bladder cancer	0.000244	0.00054	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000244	0.00205	CbGpPWpGaD
Raltegravir—Visual impairment—Doxorubicin—urinary bladder cancer	0.000243	0.000537	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—urinary bladder cancer	0.000241	0.000532	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—urinary bladder cancer	0.00024	0.000531	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—urinary bladder cancer	0.00024	0.00053	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—urinary bladder cancer	0.000239	0.000528	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000238	0.000527	CcSEcCtD
Raltegravir—Rash—Cisplatin—urinary bladder cancer	0.000238	0.000525	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—urinary bladder cancer	0.000237	0.000525	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—urinary bladder cancer	0.000237	0.000524	CcSEcCtD
Raltegravir—Erythema—Epirubicin—urinary bladder cancer	0.000237	0.000524	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—urinary bladder cancer	0.000236	0.000522	CcSEcCtD
Raltegravir—Nausea—Fluorouracil—urinary bladder cancer	0.000236	0.000522	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—urinary bladder cancer	0.000235	0.000521	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000235	0.00052	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—urinary bladder cancer	0.000235	0.00052	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—urinary bladder cancer	0.000234	0.000518	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000234	0.000517	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—urinary bladder cancer	0.000234	0.000517	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—urinary bladder cancer	0.000232	0.000513	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—urinary bladder cancer	0.00023	0.000509	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC19A1—urinary bladder cancer	0.00023	0.00193	CbGpPWpGaD
Raltegravir—Back pain—Epirubicin—urinary bladder cancer	0.000229	0.000507	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—urinary bladder cancer	0.000229	0.000506	CcSEcCtD
Raltegravir—Malaise—Methotrexate—urinary bladder cancer	0.000228	0.000505	CcSEcCtD
Raltegravir—Dizziness—Etoposide—urinary bladder cancer	0.000228	0.000505	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000228	0.000503	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—urinary bladder cancer	0.000228	0.000503	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000227	0.000502	CcSEcCtD
Raltegravir—Chills—Doxorubicin—urinary bladder cancer	0.000226	0.0005	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PRSS3—urinary bladder cancer	0.000224	0.00188	CbGpPWpGaD
Raltegravir—Nausea—Cisplatin—urinary bladder cancer	0.000224	0.000495	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—urinary bladder cancer	0.000223	0.000492	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CREBBP—urinary bladder cancer	0.000221	0.00186	CbGpPWpGaD
Raltegravir—Cough—Methotrexate—urinary bladder cancer	0.000221	0.000489	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—urinary bladder cancer	0.000221	0.000488	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00022	0.000486	CcSEcCtD
Raltegravir—Vomiting—Etoposide—urinary bladder cancer	0.000219	0.000485	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—urinary bladder cancer	0.000219	0.000485	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—urinary bladder cancer	0.000219	0.000485	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—urinary bladder cancer	0.000219	0.000485	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IGF1—urinary bladder cancer	0.000218	0.00183	CbGpPWpGaD
Raltegravir—Agitation—Epirubicin—urinary bladder cancer	0.000218	0.000482	CcSEcCtD
Raltegravir—Rash—Etoposide—urinary bladder cancer	0.000218	0.000481	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—urinary bladder cancer	0.000217	0.000481	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EGFR—urinary bladder cancer	0.000217	0.00182	CbGpPWpGaD
Raltegravir—Headache—Etoposide—urinary bladder cancer	0.000216	0.000478	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—urinary bladder cancer	0.000216	0.000478	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—urinary bladder cancer	0.000216	0.000477	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—urinary bladder cancer	0.000216	0.000477	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—urinary bladder cancer	0.000216	0.000477	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000215	0.000475	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000214	0.000474	CcSEcCtD
Raltegravir—Malaise—Epirubicin—urinary bladder cancer	0.000214	0.000473	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—urinary bladder cancer	0.000213	0.000471	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—urinary bladder cancer	0.000213	0.000471	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—urinary bladder cancer	0.000213	0.000471	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—urinary bladder cancer	0.000212	0.000469	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—urinary bladder cancer	0.00021	0.000463	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—urinary bladder cancer	0.000208	0.000461	CcSEcCtD
Raltegravir—Cough—Epirubicin—urinary bladder cancer	0.000207	0.000457	CcSEcCtD
Raltegravir—Infection—Methotrexate—urinary bladder cancer	0.000205	0.000454	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—urinary bladder cancer	0.000205	0.00172	CbGpPWpGaD
Raltegravir—Nausea—Etoposide—urinary bladder cancer	0.000205	0.000453	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—urinary bladder cancer	0.000205	0.000453	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000204	0.00045	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000203	0.000448	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—urinary bladder cancer	0.000203	0.000448	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000202	0.000448	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—urinary bladder cancer	0.000202	0.000446	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—urinary bladder cancer	0.000202	0.000446	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—urinary bladder cancer	0.000202	0.000446	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—urinary bladder cancer	0.000202	0.000446	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—urinary bladder cancer	0.000201	0.000445	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—urinary bladder cancer	0.000201	0.000444	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.0002	0.000443	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—RHOA—urinary bladder cancer	0.0002	0.00168	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.0002	0.000442	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—urinary bladder cancer	0.000199	0.000441	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—urinary bladder cancer	0.000198	0.000437	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—urinary bladder cancer	0.000197	0.000436	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—urinary bladder cancer	0.000197	0.000436	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—urinary bladder cancer	0.000195	0.000431	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—urinary bladder cancer	0.000194	0.000429	CcSEcCtD
Raltegravir—Infection—Epirubicin—urinary bladder cancer	0.000192	0.000425	CcSEcCtD
Raltegravir—Cough—Doxorubicin—urinary bladder cancer	0.000191	0.000423	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00019	0.00042	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000189	0.000419	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—urinary bladder cancer	0.000189	0.000419	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000188	0.000417	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—urinary bladder cancer	0.000188	0.000416	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000187	0.000414	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—urinary bladder cancer	0.000187	0.000414	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—urinary bladder cancer	0.000187	0.000413	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—urinary bladder cancer	0.000187	0.000413	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—urinary bladder cancer	0.000187	0.000413	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—urinary bladder cancer	0.000186	0.000412	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—urinary bladder cancer	0.000186	0.000411	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000185	0.00041	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—urinary bladder cancer	0.000185	0.00156	CbGpPWpGaD
Raltegravir—Discomfort—Doxorubicin—urinary bladder cancer	0.000185	0.000408	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—urinary bladder cancer	0.000184	0.000406	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—urinary bladder cancer	0.000183	0.000404	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—urinary bladder cancer	0.000182	0.000402	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—urinary bladder cancer	0.000181	0.000399	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—urinary bladder cancer	0.00018	0.000397	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TYMP—urinary bladder cancer	0.000179	0.00151	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000179	0.000395	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—urinary bladder cancer	0.000178	0.000394	CcSEcCtD
Raltegravir—Infection—Doxorubicin—urinary bladder cancer	0.000178	0.000393	CcSEcCtD
Raltegravir—Pain—Methotrexate—urinary bladder cancer	0.000177	0.000391	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000176	0.00039	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—urinary bladder cancer	0.000176	0.00147	CbGpPWpGaD
Raltegravir—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000388	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000175	0.000388	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—urinary bladder cancer	0.000175	0.000387	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—HRAS—urinary bladder cancer	0.000174	0.00147	CbGpPWpGaD
Raltegravir—Skin disorder—Doxorubicin—urinary bladder cancer	0.000174	0.000385	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—urinary bladder cancer	0.000174	0.000384	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000173	0.000383	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—urinary bladder cancer	0.000172	0.00038	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00017	0.000377	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—urinary bladder cancer	0.00017	0.000377	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000169	0.000374	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—urinary bladder cancer	0.000168	0.000372	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL2—urinary bladder cancer	0.000168	0.00141	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000167	0.000369	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—urinary bladder cancer	0.000167	0.000369	CcSEcCtD
Raltegravir—Constipation—Epirubicin—urinary bladder cancer	0.000165	0.000366	CcSEcCtD
Raltegravir—Pain—Epirubicin—urinary bladder cancer	0.000165	0.000366	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—urinary bladder cancer	0.000164	0.000363	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCND1—urinary bladder cancer	0.000164	0.00137	CbGpPWpGaD
Raltegravir—Abdominal pain—Methotrexate—urinary bladder cancer	0.000163	0.000361	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—urinary bladder cancer	0.000163	0.000361	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000163	0.000361	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NAT2—urinary bladder cancer	0.000162	0.00136	CbGpPWpGaD
Raltegravir—Insomnia—Doxorubicin—urinary bladder cancer	0.000162	0.000358	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000161	0.000355	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000159	0.000353	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—urinary bladder cancer	0.000159	0.000352	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—urinary bladder cancer	0.000159	0.00133	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000158	0.00133	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000158	0.00035	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTEN—urinary bladder cancer	0.000158	0.00133	CbGpPWpGaD
Raltegravir—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000158	0.000348	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000156	0.000344	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000155	0.000342	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—urinary bladder cancer	0.000154	0.000341	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—urinary bladder cancer	0.000154	0.00034	CcSEcCtD
Raltegravir—Pain—Doxorubicin—urinary bladder cancer	0.000153	0.000339	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—urinary bladder cancer	0.000153	0.000339	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—urinary bladder cancer	0.000153	0.000338	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—urinary bladder cancer	0.000153	0.000338	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000152	0.000337	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EP300—urinary bladder cancer	0.000151	0.00126	CbGpPWpGaD
Raltegravir—Asthenia—Methotrexate—urinary bladder cancer	0.000148	0.000328	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000148	0.000326	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SRC—urinary bladder cancer	0.000146	0.00123	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000146	0.000324	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—urinary bladder cancer	0.000146	0.000323	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000143	0.000315	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—urinary bladder cancer	0.000142	0.000314	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000142	0.000313	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000142	0.000313	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—urinary bladder cancer	0.000141	0.000313	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—RRM2—urinary bladder cancer	0.00014	0.00118	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—urinary bladder cancer	0.000139	0.000307	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—urinary bladder cancer	0.000137	0.000303	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—urinary bladder cancer	0.000137	0.000302	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—urinary bladder cancer	0.000132	0.000293	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000132	0.000292	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—urinary bladder cancer	0.000131	0.000291	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—urinary bladder cancer	0.000131	0.0011	CbGpPWpGaD
Raltegravir—Rash—Methotrexate—urinary bladder cancer	0.00013	0.000288	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—urinary bladder cancer	0.00013	0.000288	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ENO2—urinary bladder cancer	0.00013	0.00109	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPGDS—urinary bladder cancer	0.00013	0.00109	CbGpPWpGaD
Raltegravir—Headache—Methotrexate—urinary bladder cancer	0.00013	0.000286	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—urinary bladder cancer	0.000128	0.000284	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EGFR—urinary bladder cancer	0.000128	0.00108	CbGpPWpGaD
Raltegravir—Dizziness—Epirubicin—urinary bladder cancer	0.000128	0.000283	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—urinary bladder cancer	0.000127	0.00028	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTT1—urinary bladder cancer	0.000126	0.00106	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—urinary bladder cancer	0.000123	0.000272	CcSEcCtD
Raltegravir—Nausea—Methotrexate—urinary bladder cancer	0.000123	0.000272	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000122	0.000271	CcSEcCtD
Raltegravir—Rash—Epirubicin—urinary bladder cancer	0.000122	0.00027	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—urinary bladder cancer	0.000122	0.00027	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KRAS—urinary bladder cancer	0.000121	0.00102	CbGpPWpGaD
Raltegravir—Headache—Epirubicin—urinary bladder cancer	0.000121	0.000268	CcSEcCtD
Raltegravir—Dizziness—Doxorubicin—urinary bladder cancer	0.000118	0.000262	CcSEcCtD
Raltegravir—Nausea—Epirubicin—urinary bladder cancer	0.000115	0.000254	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—urinary bladder cancer	0.000114	0.000252	CcSEcCtD
Raltegravir—Rash—Doxorubicin—urinary bladder cancer	0.000113	0.00025	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—urinary bladder cancer	0.000113	0.000249	CcSEcCtD
Raltegravir—Headache—Doxorubicin—urinary bladder cancer	0.000112	0.000248	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TP53—urinary bladder cancer	0.000108	0.000905	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—urinary bladder cancer	0.000106	0.000235	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NQO1—urinary bladder cancer	0.000104	0.000877	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—urinary bladder cancer	0.000103	0.000865	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	8.71e-05	0.000732	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMS—urinary bladder cancer	8.1e-05	0.00068	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	8.01e-05	0.000672	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	8.01e-05	0.000672	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GPX1—urinary bladder cancer	7.67e-05	0.000644	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	7.53e-05	0.000632	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	7.08e-05	0.000594	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—urinary bladder cancer	5.74e-05	0.000482	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	5.51e-05	0.000463	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	4.51e-05	0.000379	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—urinary bladder cancer	3.94e-05	0.000331	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EP300—urinary bladder cancer	3.75e-05	0.000315	CbGpPWpGaD
